Skip to main content

Table 2 Univariate and multivariate logistic regression analysis to identify predictors of acute GVHD related to cyclosporine administration

From: Low cyclosporine concentrations in children and time to acute graft versus host disease

CharacteristicsUnadjusted OR (95% CI)Adjusted OR (95% CI)
Model IModel IIModel III
Age ≥ 12 (years)0.474 (0.163–1.375)1.444 (0.294–7.081)4.936 (0.413–59.061)2.447 (0.22–27.203)
Male0.987 (0.357–2.729)1.585 (0.389–6.468)1.626 (0.23–11.471)1.102 (0.164–7.393)
Mismatched donor1.633 (0.476–5.600)1.693 (0.358–7.996)0.582 (0.04–8.524)1.479 (0.175–12.480)
Myeloablative conditioning regimen0.612 (0.206–1.822)0.376 (0.084–1.692)0.162 (0.018–1.450)0.146 (0.022–0.989)*
Methotrexate0.267 (0.072–0.993)*0.264 (0.041–1.721)0.158 (0.009–2.830) 
Kidney injury grade 0–1 (NCI CTCAE)8.000 (1.556–41.134)*9.828 (1.434–67.339)*1.800 (0.184–17.596) 
Low CsA concentrations at lag time before aGVHD
 Lag 0–6 days9.286 (2.882–29.917)***11.017 (2.336–51.947)**  
 Lag 7–13 days58.556 (10.632–322.499)*** 108.196 (7.725–1515.48)*** 
 Lag 14–20 days11.111 (1.976–62.466)***  12.120 (1.064–138.13)*
  1. Model I included age, sex, mismatched donor, myeloablative conditioning regimen, methotrexate use, kidney injury (NCI CTCAE grade 2 or higher), and low CsA concentrations at lag days 0–6 before aGVHD. After considering multicollinearity, Model II and III included low CsA concentrations at lag days 7–13 and 14–20 days, respectively
  2. NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, CsA cyclosporine, aGVHD acute graft-versus-host disease, OR odds ratio
  3. *P < 0.05, **P < 0.01, ***P < 0.001